RT Journal Article
SR Electronic
T1 Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the Delta variant epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.17.22269394
DO 10.1101/2022.01.17.22269394
A1 Maeda, Haruka
A1 Saito, Nobuo
A1 Igarashi, Ataru
A1 Ishida, Masayuki
A1 Suami, Kazuya
A1 Yagiuchi, Ai
A1 Kimura, Yuya
A1 Komino, Masaru
A1 Arai, Hiromi
A1 Morikawa, Toru
A1 Motohashi, Iori
A1 Miyazawa, Rei
A1 Moriyama, Tetsu
A1 Kamura, Hiroshi
A1 Terada, Mayumi
A1 Kuwamitsu, Osamu
A1 Hayakawa, Tomoichiro
A1 Sando, Eiichiro
A1 Ohara, Yasuji
A1 Teshigawara, Osamu
A1 Suzuki, Motoi
A1 Morimoto, Konosuke
YR 2022
UL http://medrxiv.org/content/early/2022/01/23/2022.01.17.22269394.abstract
AB Background Although high vaccine effectiveness of messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines was reported in studies in several countries, data is limited from Asian countries, especially against the Delta (B.1.617.2) variant.Methods We conducted a multicenter test-negative case-control study in patients aged ≥16 visiting hospitals or clinics with signs or symptoms consistent with COVID-19 from July 1 to September 30, 2021, when the Delta variant was dominant (≥90% of severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] infections) nationwide in Japan. Vaccine effectiveness of BNT162b2 or mRNA-1273 against symptomatic SARS-CoV-2 infections was evaluated. Waning immunity among patients aged 16 to 64 was also assessed.Results We enrolled 1936 patients, including 396 test-positive cases and 1540 test-negative controls for SARS-CoV-2. The median age was 49 years, 53.4% were male, and 34.0% had underlying medical conditions. Full vaccination (receiving two doses ≥14 days before symptom onset) was received by 6.6% of cases and 38.8% of controls. Vaccine effectiveness of full vaccination against symptomatic SARS-CoV-2 infections was 88.7% (95% confidence interval [CI], 78.8–93.9) among patients aged 16 to 64 and 90.3% (95% CI, 73.6–96.4) among patients aged ≥65. Among patients aged 16 to 64, vaccine effectiveness within one to three months after full vaccination was 91.8% (95% CI, 80.3–96.6), and was 86.4% (95% CI, 56.9–95.7) within four to six months.Conclusions mRNA COVID-19 vaccines had high effectiveness against symptomatic SARS-CoV-2 infections in Japan during July 1 to September 30, 2021, when the Delta variant was dominant nationwide.Competing Interest StatementThe Department of Respiratory Infections, Institute of Tropical Medicine, Nagasaki University has received grants not directly related to this surveillance from Pfizer Inc. The Department of Health Economics and Outcomes Research, the Graduate School of Pharmaceutical Science, and the University of Tokyo have received grants not directly related to this surveillance from Takeda Pharmaceutical Company Limited.Funding StatementThis work was supported by Japan Agency for Medical Research and Development under grant number, JP21fk0108612.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board (IRB) at the Institute of Tropical Medicine, Nagasaki University (approval no. 210225257) and the study sites. For the study sites without IRBs, this study was collectively reviewed by the Institute of Tropical Medicine IRB, Nagasaki University.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are not available because the intellectual property agreement with the facilities has not been completed.